- Bristol-Myers, SNY Win Plavix Damages
- Sanofi's Balanced Model Looks Undervalued
- 4 Companies That Have Institutional Investors On The Sidelines
- The Zacks Analyst Blog Highlights: Western Union, Mylan, Valeant Pharmaceuticals, Sanofi and Pfizer
- Sanofi's CEO Discusses Q4 2011 Results - Earnings Call Transcript
- Eurodebt Woes for the European Drug Sector
- Mylan Acquires Two Generics
- [$$] Sanofi Warns on 2012 Earnings
- Apotex pays Bristol, Sanofi damages over Plavix
- Roche Hostile Bid for Illumina is Just Getting Started
- InPlay: Sanofi-Aventis' Genzyme reports four year data from Phase 2 trial of Gaucher Disease oral compound - suggests sustained or continued improvement across all endpoints
- Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints







